Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Recommendation of "Hold" from Brokerages

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) has been assigned a consensus rating of "Hold" from the five ratings firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $4.00.

A number of research analysts recently issued reports on MCRB shares. StockNews.com lowered Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday. The Goldman Sachs Group reduced their price target on shares of Seres Therapeutics from $1.00 to $0.75 and set a "sell" rating for the company in a report on Friday, March 14th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $1.25 price objective on shares of Seres Therapeutics in a report on Thursday, March 20th.

Institutional Investors Weigh In On Seres Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Avantax Advisory Services Inc. raised its holdings in Seres Therapeutics by 170.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 28,500 shares in the last quarter. Jane Street Group LLC increased its position in shares of Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 37,866 shares during the period. Virtu Financial LLC raised its stake in shares of Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock worth $56,000 after buying an additional 18,191 shares in the last quarter. Northern Trust Corp raised its stake in shares of Seres Therapeutics by 20.4% in the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock worth $218,000 after buying an additional 44,461 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock valued at $363,000 after buying an additional 43,700 shares during the period. Institutional investors and hedge funds own 59.34% of the company's stock.

Remove Ads

Seres Therapeutics Stock Up 1.7 %

MCRB stock traded up $0.01 during midday trading on Tuesday, reaching $0.59. The company had a trading volume of 810,367 shares, compared to its average volume of 3,249,733. The stock has a 50 day moving average price of $0.72 and a 200 day moving average price of $0.79. The firm has a market capitalization of $102.96 million, a PE ratio of -2.57 and a beta of 2.54. Seres Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $1.53.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.